Clinical Trial

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Study acronym: STOP-PKD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.
Protocol Amendment History 1 change
notable Trial sites expanded: 27 -> 30 locations 2026-06-16
Trial Details
NCT Number NCT07280585
Lead Sponsor University of Cologne
Collaborators: German Research Foundation
Conditions Polycystic Kidney, Autosomal Dominant
Enrollment 420 participants
Start Date 2025-12-16
Primary Completion 2030-05-15 (estimated)
Study Completion 2030-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-28